Orexo AB is getting an up-front payment of $10 million and will get another $11.5 million in research funding on the back of an alliance with Johnson & Johnson subsidiaries Ortho-McNeil-Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV to develop two of its preclinical programs, which target pathways involved in arachidonic acid metabolism. For good measure, J&J, of New Brunswick, N.J., is throwing an as yet unselected third compound of its own into the mix. (BioWorld International)